文献速递神经肿瘤功能神经外科

WHO 2021分类岛叶胶质瘤唤醒脑定位术后的预后因素与肿瘤功能结局

Prognostic Factors and Oncofunctional Outcomes of WHO 2021-Classified Insular Gliomas Undergoing Awake Brain Mapping.
PubMed 文献 · World Neurosurg · 2026-07-24

该回顾性研究纳入36例接受唤醒手术的岛叶胶质瘤患者(含IDH突变型低级别胶质瘤23例、IDH野生型伴低级别组织学GBM 5例、IDH野生型组织学GBM 8例),评估预后因素及神经功能与认知功能保留情况。结果显示唤醒术后Wechsler记忆量表修订版的一般记忆与延迟回忆评分显著改善,IDH突变型低级别胶质瘤中位总生存期显著长于IDH野生型GBM;组织学GBM、IDH状态和最终切除程度≥90%是总生存期的显著预测因素。

要点

  • 唤醒功能定位可减少神经功能缺损并保护神经认知功能。
  • 组织学GBM、IDH野生型及切除程度<90%与更差的总生存期相关。
  • IDH突变型低级别胶质瘤中位总生存期未达到,显著优于IDH野生型GBM。

核心结论

  • 组织学GBM、IDH突变状态和最终切除程度≥90%是岛叶胶质瘤患者总生存期的显著预测因素。
  • 唤醒功能定位是岛叶胶质瘤的有用手术方式,可减少神经功能缺损并保护神经认知功能。

研究设计与样本

  • 回顾性分析2012年12月至2021年1月间连续36例接受唤醒手术的岛叶胶质瘤患者,包括低级别胶质瘤和胶质母细胞瘤。

主要发现

  • IDH突变型低级别胶质瘤23例,IDH野生型伴低级别组织学特征的GBM 5例,IDH野生型组织学GBM 8例。
  • 唤醒术后Wechsler记忆量表修订版一般记忆评分较术前显著改善(Z=-0.56,P=0.04)。
  • 唤醒术后延迟回忆评分较术前显著改善(Z=-0.73,P=0.04)。
  • IDH突变型低级别胶质瘤中位总生存期未达到,显著长于IDH野生型伴低级别组织学GBM的15个月(P<0.001)。
  • IDH突变型低级别胶质瘤中位总生存期未达到,显著长于IDH野生型组织学GBM的12个月(P<0.001)。

关键数值与推荐

  • 多因素模型显示总生存率与病理相关:组织学GBM对比组织学低级别胶质瘤,HR=6.41,P=0.04。
  • 多因素模型显示总生存率与IDH1或IDH2状态相关:突变对比野生型,HR=0.04,P=0.01。
  • 多因素模型显示总生存率与最终切除程度相关:≥90%对比<90%,HR=0.12,P=0.04。

临床怎么用

  • 对岛叶胶质瘤患者可考虑唤醒功能定位手术以保护神经认知功能。
  • 术后应结合组织学类型、IDH突变状态和切除程度评估总生存预后。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study aimed to evaluate prognostic factors and oncofunctional outcomes, including neurological and neurocognitive preservation, in patients with World Health Organization 2021-classified insular lower-grade gliomas and glioblastoma who underwent awake brain mapping. METHODS: We retrospectively analyzed 36 consecutive patients with insular glioma, including LrGGs and GBM, who underwent awake surgery between December 2012 and January 2021. RESULTS: The group of patients with IDH-mutant LrGG included 23 cases, while those with IDH-wildtype GBM with histological features of LrGG and GBM included 5 and 8 patients, respectively. The postoperative mean Wechsler Memory Scale-Revised scores for General Memory (Z=-0.56, P=0.04) and Delayed Recall (Z=-0.73, P=0.04) significantly improved compared with their preoperative values after awake surgery. The median overall survival (OS) of patients with IDH-mutant LrGGs was significantly longer (not reached) than that of patients with IDH-wildtype GBM with histological LrGG (15 months, P<0.001) and IDH-wildtype GBM with histological GBM (12 months, P<0.001). The multivariate models showed that OS rates were significantly related to pathology [histological GBM versus histological LrGG, hazard ratio (HR)=6.41, P=0.04], IDH1 or IDH2 status (mutation vs. wildtype, HR=0.04, P=0.01), and final EOR (≥90% vs. <90%, HR=0.12, P=0.04). CONCLUSIONS: Histological GBM, IDH mutation status, and EOR ≥90% were significant predictors of OS in patients with insular gliomas. Moreover, awake functional mapping for insular gliomas is a useful surgical approach, as it minimizes neurological deficits and allows preservation of neurocognitive functions.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Motomura K, Mitsuya K, Kibe Y, et al. Prognostic Factors and Oncofunctional Outcomes of WHO 2021-Classified Insular Gliomas Undergoing Awake Brain Mapping. World Neurosurg. 2026. PMID: 42498227. doi:10.1016/j.wneu.2026.125210

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。